HDAC9 and hematologic disorder: Since then, three other HDAC inhibitors, panobinostat (pan-HDAC inhibitor), belinostat (pan-HDAC inhibitor) and romidepsin (class I HDAC inhibitor), have also been approved by FDA for the treatment of hematological malignancies [137].